Janus kinases to jakinibs : from basic insights to clinical practice

Show simple item record

dc.contributor.author Gadina, Massimo
dc.contributor.author Le, Mimi T.
dc.contributor.author Schwartz, Daniella M.
dc.contributor.author Silvennoinen, Olli
dc.contributor.author Nakayamada, Shingo
dc.contributor.author Yamaoka, Kunihiro
dc.contributor.author O'Shea, John J.
dc.date.accessioned 2021-03-11T13:23:01Z
dc.date.available 2021-03-11T13:23:01Z
dc.date.issued 2019-02
dc.identifier.citation Gadina , M , Le , M T , Schwartz , D M , Silvennoinen , O , Nakayamada , S , Yamaoka , K & O'Shea , J J 2019 , ' Janus kinases to jakinibs : from basic insights to clinical practice ' , Rheumatology , vol. 58 , pp. 4-16 . https://doi.org/10.1093/rheumatology/key432
dc.identifier.other PURE: 132263675
dc.identifier.other PURE UUID: 0738c0fa-e7ed-4c74-99d2-35a80a57d903
dc.identifier.other WOS: 000462720600002
dc.identifier.uri http://hdl.handle.net/10138/327839
dc.description.abstract Cytokines are critical mediators of diverse immune and inflammatory diseases. Targeting cytokines and cytokine receptors with biologics has revolutionized the treatment of many of these diseases, but targeting intracellular signalling with Janus kinase (JAK) inhibitors (jakinibs) now represents a major new therapeutic advance. We are still in the first decade since these drugs were approved and there is still much to be learned about the mechanisms of action of these drugs and the practical use of these agents. Herein we will review cytokines that do, and just as importantly, do not signal by JAKs, as well as explain how this relates to both efficacy and side effects in various diseases. We will review new, next-generation selective jakinibs, as well as the prospects and challenges ahead in targeting JAKs. en
dc.format.extent 13
dc.language.iso eng
dc.relation.ispartof Rheumatology
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject cytokines
dc.subject signal transduction
dc.subject Janus kinases
dc.subject kinase inhibitors
dc.subject autoimmunity
dc.subject inflammation
dc.subject MODIFYING ANTIRHEUMATIC DRUG
dc.subject COMBINED IMMUNE-DEFICIENCY
dc.subject SELECTIVE JAK-1 INHIBITOR
dc.subject RHEUMATOID-ARTHRITIS
dc.subject INADEQUATE RESPONSE
dc.subject TYROSINE KINASE
dc.subject PRIMARY MYELOFIBROSIS
dc.subject TRANSCRIPTION FACTORS
dc.subject VX-509 DECERNOTINIB
dc.subject DISEASE-ACTIVITY
dc.subject 1182 Biochemistry, cell and molecular biology
dc.subject 3121 General medicine, internal medicine and other clinical medicine
dc.title Janus kinases to jakinibs : from basic insights to clinical practice en
dc.type Review Article
dc.contributor.organization Institute of Biotechnology
dc.contributor.organization University of Helsinki
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1093/rheumatology/key432
dc.relation.issn 1462-0324
dc.rights.accesslevel openAccess
dc.type.version acceptedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
Gadina_et_al_Rh ... us_kinases_to_jakinibs.pdf 936.1Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record